CT103A CAR T-cell Therapy Leads to Strong Anti-cancer Responses in Relapsed or Refractory Multiple Myeloma Patients, Trial Shows
CT103A, a fully-human anti-B-cell mature antigen (BCMA)…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Ygalo Continues to Induce Clinically Meaningful Responses in Relapsed or Refractory Multiple Myeloma, Phase 1/2 Trials Show
Ygalo (melflufen) combination therapy continues to lead…
Early Data Show Positive Activity of Iberdomide Against Heavily Treated MM
Interim data from an ongoing Phase 1/2 clinical trial…
AMG 420 Immunotherapy Effective in Difficult-to-treat Multiple Myeloma, Early Study Results Show
The investigational immunotherapy AMG 420 lessened tumor burden…
Clinical Trial Results Suggest Isatuximab Improves Survival in People with RRMM
Isatuximab, a potential therapeutic antibody, can improve survival in…
Similar Efficacy and Safety Seen Between Under-the-Skin Formulation and Intravenous Darzalex for Myeloma, Phase 3 Trial Shows
An under-the-skin formulation of daratumumab is as effective as…
